본문 바로가기

Antitumor activity of sorafenib-incorporated nanoparticles of dextran/poly(dl-lactide-co-glycolide) block copolymer

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
피인용
Web of Science 46
JCR IF
JCR 2011 2.726
ISSN
1931-7573

저자

  1. 김도형제1저자National Research and Development Center for Hepatobiliary Cancer, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, South Korea
  2. 김민대Department of Internal Medicine, Medical Research Institute, Pusan National University, School of Medicine and Medical Research Institute, South Korea
  3. 최철웅Department of Internal Medicine, Medical Research Institute, Pusan National University, School of Medicine and Medical Research Institute, South Korea
  4. 정정욱National Research and Development Center for Hepatobiliary Cancer, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, South Korea
  5. 차승헌National Research and Development Center for Hepatobiliary Cancer, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, South Korea
  6. 김시현National Research and Development Center for Hepatobiliary Cancer, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, South Korea
  7. Shim, Yong-HoNational Research and Development Center for Hepatobiliary Cancer, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, South Korea
  8. 정영일교신저자National Research and Development Center for Hepatobiliary Cancer, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, South Korea
  9. 강대환National Research and Development Center for Hepatobiliary Cancer, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, South Korea

초록

Sorafenib-incoporated nanoparticles were prepared using a block copolymer that is composed of dextran and poly (DL-lactide-co-glycolide) [DexbLG] for antitumor drug delivery. Sorafenib-incorporated nanoparticles were prepared by a nanoprecipitation-dialysis method. Sorafenib-incorporated DexbLG nanoparticles were uniformly distributed in an aqueous solution regardless of the content of sorafenib. Transmission electron microscopy of the sorafenib-incorporated DexbLG nanoparticles revealed a spherical shape with a diameter < 300 nm. Sorafenib-incorporated DexbLG nanoparticles at a polymer/drug weight ratio of 40:5 showed a relatively uniform size and morphology. Higher initial drug feeding was associated with increased drug content in nanoparticles and in nanoparticle size. A drug release study revealed a decreased drug release rate with increasing drug content. In an in vitro anti-proliferation assay using human cholangiocarcinoma cells, sorafenib-incorporated DexbLG nanoparticles showed a similar antitumor activity as sorafenib. Sorafenib-incorporated DexbLG nanoparticles are promising candidates as vehicles for antitumor drug targeting.

키워드

sorafenibpolymeric micelledextranpoly(DL-lactide-co-glycolide)MICELLESL-ASPARTATE)

식별자

WoS UID
000315640300001